

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew R. Marks
U.S. Serial No.: 10/809,089
Confirmation No.: 7653
Filing Date: March 25, 2004
Group Art Unit: 1609
Examiner: PACKARD, BENJAMIN J
Title: **NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE
DRUGS THAT TARGET THE LEAK IN THE RYANODINE
RECEPTOR (RYP2) AND USES THEREOF**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT WITH AMENDMENT

This paper is filed in reply to the Office Action of July 10, 2007. The reply was originally due on August 10, 2007. Applicants request three-month extension, which makes the reply due on November 10 2007. Therefore, this paper is being filed timely. The Commissioner is authorized to charge any fees that might be due to Deposit Account No. 08-0219.

In response to the Restriction Requirement, Applicants elect, without traverse, the claims of Group II, and the species of compound S36 as encompassed by chemical formula (g).

Amendment to the Claims begins on page 2.

Remarks begin on page 10.